OncoAlert 4Sight 摘要将在 #ESMO26 上展示
配对活检多组学分析揭示了转移性乳腺癌（MBC）中抗体-药物偶联物（ADC）耐药的靶点非依赖性机制
🎙️ @PTarantinoMD
🔬 配对活检多组学研究（n=26）：治疗前与进展后 MBC 活检，接受 T-DXd、sacituzumab govitecan 或两者。#BreastCancer
➡️ T-DXd：HER2 在 57% 中下降，但无病例变为 HER2-null
➡️ SG：TROP2 无一致性下调（5/14 上调，3/14 下调）
➡️ >50% 出现外排转运体（ABCB1、ABCC1）上调；功能验证显示药物载荷积累减少且 ADC 敏感性下降
✅ ADC 耐药似乎由超出靶点调节的复杂适应驱动，凸显药物外排、转运和细胞应激反应。
（4Sight 基于 ESMO 网站公开的摘要制作）
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @SirohiBhawna @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H
1850 浏览 · 9 赞 · 6 转发 · 0 回复
Sacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgComparative effectiveness of trastuzumab deruxtecan versus sacituzumab govitecan in HER2-negative metastatic breast cancer: A real-world analysis with propensity score matching
https://esmocongress.esmo.orgSacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Results From a Phase 2 Study (2870-002/SKB264-II-06)
https://esmocongress.esmo.orgSacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7
https://esmocongress.esmo.org来源：OncoAlert · x.com